EPALINGES, Switzerland,
Dec. 1, 2016 /PRNewswire/
-- Mymetics Corporation (OTCQB: MYMX), a pioneer and leader in
the research and development of virosome-based vaccines to prevent
transmission of human infectious diseases, announced today that its
subsidiary Mymetics B.V. has agreed on a research project with
Sanofi Pasteur, the vaccine division of Sanofi (NYSE: SNY). The
project will investigate the immunogenicity of influenza vaccines
based on Mymetics' proprietary virosome technology platform in
pre-clinical settings. If this project is successful it could
result in a further and more extensive collaboration between the
two companies.
"We are very excited to start this initial collaboration project
with Sanofi, a world leader in the vaccine industry," said
Ronald Kempers, CEO of Mymetics. "We
look forward to show that our proprietary virosome technology and
more than 30 years of virosome vaccines expertise can make a
valuable difference in improving the effectiveness and cost
competitiveness of influenza vaccines."
About Mymetics
Mymetics Corp. (OTCQB: MYMX) is a Swiss
based biotechnology company, with a Research Lab in the Netherlands, focused on the development of
next-generation preventative vaccines for infectious diseases. It
currently has five vaccines in its pipeline: HIV-1/AIDS,
intra-nasal Influenza, Malaria, Chikungunya, Herpes Simplex Virus
and the RSV vaccine. HIV, malaria and intra-nasal influenza
vaccines have successfully finished Phase 1 clinical trials, while
the others are in the pre-clinical phase.
Mymetics' core technology and expertise are in the use of
virosomes, lipid-based carriers containing functional fusion viral
proteins and natural membrane proteins, in combination with
rationally designed antigens. Mymetics' vaccines are designed to
induce protection against early transmission and infection,
focusing on the mucosal immune response as a first-line defense, in
combination with humoral and cellular immune responses as a
second-line defense, which can be essential for the development of
an effective vaccine.
Mymetics' unique approach is being validated through
partnerships with leading pharmaceutical or research organizations,
including projects with PATH-MVI and the Bill and Melinda Gates
Foundation.
For further information, please visit www.mymetics.com.
Forward looking statements
The Private Securities
Litigation Reform Act of 1995 provides a "safe harbor" for
forward-looking statements, which are identified by the words
"believe," "expect," "anticipate," "intend," "plan" and similar
expressions. The statements contained herein which are not based on
historical facts are forward-looking statements that involve known
and unknown risks and uncertainties that could significantly affect
our actual results, performance or achievements in the future and,
accordingly, such actual results, performance or achievements may
materially differ from those expressed or implied in any
forward-looking statements made by or on our behalf. These risks
and uncertainties include, but are not limited to, risks associated
with our ability to successfully develop and protect our
intellectual property, our ability to raise additional capital to
fund future operations and compliance with applicable laws and
changes in such laws and the administration of such laws. See
Mymetics' most recent Form 10-K for a discussion of such risks,
uncertainties and other factors. Readers are cautioned not to place
undue reliance on these forward- looking statements which speak
only as of the date the statements were made.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/mymetics-starts-research-project-with-sanofi-for-influenza-vaccines-300370942.html
SOURCE Mymetics Corporation